In 2006, the company received the main business revenue of RMB 321.1685 million, of which the pharmaceutical industry accounted for 62.83%; the profit of main business reached RMB 154.1201 million and, the net profit amounted to RMB 19.6635 million.

Xueshuantong Freeze-Dry Powder for Injection, the company's core pharmaceutical product, is an important variety in cardiovascular and cerebrovascular fields. At present, the company's full-loaded monthly production capacity can not meet the increased market demand, so some products are contracted to Chongqing Yaoyou Pharmaceutical temporarily. It is estimated that the sales volume of Xueshuantong Freeze-Dry Powder for Injection will be 25 million doses in 2007, and 40 million in 2008, 50 million in 2009.